Kairos Pharma Ltd
KAPAHealthcare·Biotechnology·USA·Nano·AMEX·Nov 11 • 3:49 PM ET
0.5099+0.0359 (7.57%)
2026-11-12 05:33 CET
Market cap
1.73 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-5.80 USD m
Free cash flow, TTM
- USD m
EPS diluted, TTM
-1.95
P/E
-
Price
KAPA against its 20, 50 and 200-day averages2050200beatearnings
93.0% under the 52-week high of 7.28 on 8 Jan 2026. 52-week low 0.42 on 3 Nov 2026. Last 15 sessions, 43.5% high to low
Volume 0.06× normal · the line is the 50-bar volume average
Profile
KAPA52-week range, 1% of the way up
0.427.28
Kairos Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of novel and transformative drug therapies to treat cancer. It focuses on the research and development of immunotherapies for oncology. The company was founded by John S. Yu on June 17, 2013 and is headquartered in Los Angeles, CA.
| Employees | 4 |
|---|---|
| IPO | Sep 16, 2024 |
| Beta | 1.83 |
| ATR, 14d | 0.09 |
| Rel volume | 0.06 |
| Short float | 3.74% |
| Insider own | 33.61% |
| Inst own | 3.64% |
Snapshot
6 groupsValuation
| Index | - |
|---|---|
| Market Cap | 1.72M |
| Enterprise Value | -0.91M |
| Income | -5.80M |
| Sales | 0.00M |
| Book/sh | 1.37 |
| Cash/sh | 0.78 |
| Dividend Est. | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Dividend Gr. 3/5Y | - - |
| Payout | - |
| Employees | 4 |
| IPO | Sep 16, 2024 |
Ratios
| P/E | - |
|---|---|
| Forward P/E | - |
| PEG | - |
| P/S | - |
| P/B | 0.37 |
| P/C | 0.65 |
| P/FCF | - |
| EV/EBITDA | - |
| EV/Sales | - |
| Quick Ratio | 11.98 |
| Current Ratio | 11.98 |
| Debt/Eq | 0.00 |
| LT Debt/Eq | 0.00 |
| Option/Short | No / Yes |
Earnings
| EPS (ttm) | -1.95 |
|---|---|
| EPS next Y | -4.69 |
| EPS next Q | -0.63 |
| EPS this Y | -23.33% |
| EPS next Y | -81.08% |
| EPS next 5Y | - |
| EPS past 3/5Y | -53.50% -29.28% |
| Sales past 3/5Y | - - |
| EPS Y/Y TTM | 11.64% |
| Sales Y/Y TTM | - |
| EPS Q/Q | 21.56% |
| Sales Q/Q | - |
| Earnings | Sep 02 |
| EPS/Sales Surpr. | 0.00% - |
Ownership
| Insider Own | 33.61% |
|---|---|
| Insider Trans | 0.00% |
| Inst Own | 3.64% |
| Inst Trans | 6.97% |
| ROA | -104.32% |
| ROE | -113.96% |
| ROIC | -138.51% |
| Gross Margin | - |
| Oper. Margin | - |
| Profit Margin | - |
| SMA20 | -4.37% |
| SMA50 | -54.71% |
| SMA200 | -82.04% |
| Trades | - |
Technical
| Shs Outstand | 3.06M |
|---|---|
| Shs Float | 2.25M |
| Short Float | 3.74% |
| Short Ratio | 0.23 |
| Short Interest | 0.08M |
| 52W High | 7.28 -93.00% |
| 52W Low | 0.42 21.93% |
| Volatility | 10.86% 11.38% |
| ATR (14) | 0.09 |
| RSI (14) | 30.15 |
| Beta | 1.83 |
| Rel Volume | 0.06 |
| Avg Volume | 360.32K |
| Volume | 21,534 |
Performance
| Perf Week | 4.12% |
|---|---|
| Perf Month | -38.47% |
| Perf Quarter | -79.77% |
| Perf Half Y | -84.30% |
| Perf YTD | -89.74% |
| Perf Year | -91.68% |
| Perf 3Y | - |
| Perf 5Y | - |
| Perf 10Y | - |
| Recom | 1.00 |
| Target Price | 84.00 |
| Prev Close | 0.47 |
| Price | 0.51 |
| Change % | 7.57% |
Peers
Mkt capHeld by
AUM| Ticker | Company | AUM |
|---|---|---|
| VXF | Vanguard Extended Market Index ETF | AUM: 30.47B |
News
latest 14 of 94- Kairos Pharma Recognized by Biotech Breakthrough Awards in Oncology (Business Wire) -7.17%
- Kairos Pharma Presents at United Scientific Group's 11th International Conference on Cancer Research & Drug Development (Business Wire) +6.65%
- Kairos Pharma Reports Positive, Statistically Significant Interim Efficacy Data from Phase 2 Trial of ENV-105 in Metastatic Prostate Cancer (Business Wire) -25.81%
- Kairos Pharma to Present and Moderate at Discovery on Target Conference in Boston, MA (Business Wire)
- Kairos Pharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference (Business Wire) -6.21%
- Kairos Pharma Announces 1-for-7 Reverse Stock Split (Business Wire) -20.00%
- Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance XOFIGO Activity in Metastatic Prostate Cancer (Business Wire) -12.65%
- CEO.CA's Inside the Boardroom: Kairos Pharma Might Change Cancer Treatment Forever (TMX Newsfile) -6.47%
- Kairos Pharma Reports Breakthrough Interim Safety Data in Phase 1 Trial of ENV-105 in EGFR-Mutated Lung Cancer Patients - Targeting a $10 Billion Drug Resistance Market (Business Wire)
- Kairos Pharma Recaps Important Acquisitions and Details Plans for the Balance of 2026 in Letter to Shareholders (Business Wire)
- Kairos Pharma Receives GHP Magazine's Healthcare & Pharmaceutical Award (Business Wire) +6.10%
- Kairos Pharma, Ltd. to Present at the LD Micro Invitational XVI (Newsfile)
- Kairos Pharma, Ltd. Sets Annual Meeting of Shareholder Date and Provides Update on Its Annual Filings (Business Wire) -5.36%
- Kairos Pharma Recognized with Pinnacle Award for Excellence in Healthcare Innovation (Business Wire)
Quarterly earnings
actual against estimate| Period | Reported | EPS act | EPS est | EPS rep | Sales act | Sales est | Analysts |
|---|---|---|---|---|---|---|---|
| 2026Q2 | 2026-09-02 | -0.560 | -0.560 | -0.454 | 0.00 | 0.00 | 2 |
| 2026Q1 | 2026-06-03 | -0.560 | -0.560 | -0.551 | 0.00 | 0.00 | 1 |
| 2025Q4 | 2026-02-25 | -0.490 | -0.131 | -0.459 | 0.00 | 0.00 | 2 |
| 2025Q3 | 2025-12-03 | -0.487 | -0.558 | -0.484 | 0.00 | 0.00 | 3 |
| 2025Q2 | 2025-09-03 | -0.566 | -0.490 | -0.578 | 0.00 | 0.00 | 3 |
| 2025Q1 | 2025-05-28 | -0.490 | -0.350 | -0.556 | 0.00 | 0.00 | 3 |
| 2024Q4 | 2025-02-26 | -0.350 | -0.420 | -0.499 | 0.00 | 0.00 | 2 |
| 2024Q3 | 2024-11-27 | -0.350 | -0.140 | -0.571 | 0.00 | 0.00 | 1 |
| 2024Q2 | 2024-08-28 | -0.140 | - | -0.138 | 0.00 | - | - |
| 2026Q3 | - | - | -0.630 | - | - | 0.00 | 1 |
| 2026Q4 | - | - | -0.770 | - | - | 0.00 | 1 |
| 2027Q1 | - | - | -0.630 | - | - | - | 1 |
| 2027Q2 | - | - | -0.560 | - | - | - | 1 |
| 2027Q3 | - | - | -0.560 | - | - | - | 1 |
| 2027Q4 | - | - | -0.630 | - | - | - | 1 |
| 2028Q1 | - | - | -0.958 | - | - | 0.00 | 1 |
Annual earnings
| Period | EPS act | EPS est | EPS rep | Sales act | Sales est |
|---|---|---|---|---|---|
| 2024FY | -1.773 | -0.980 | -1.326 | 0.00 | 0.00 |
| 2025FY | -2.100 | -1.745 | -1.745 | 0.00 | 0.00 |
| 2026FY | - | -2.590 | - | - | 0.00 |
| 2027FY | - | -4.690 | - | - | 0.00 |
| 2028FY | - | -5.110 | - | - | 0.00 |
| 2029FY | - | -2.590 | - | - | - |
| 2030FY | - | 2.520 | - | - | 55.58 |
Estimate revisions
last 14 periods| Period | Type | Date | Estimates | Up | Down | Mean | Low | High |
|---|---|---|---|---|---|---|---|---|
| 2026Q3 | S | 2026-09-02 | 1 | 0 | 0 | 0.00 | 0.00 | 0.00 |
| 2026Q3 | S | 2026-06-03 | 1 | 0 | 0 | 0.00 | 0.00 | 0.00 |
| 2026Q3 | S | 2026-02-25 | 1 | 0 | 0 | 0.00 | 0.00 | 0.00 |
| 2026Q3 | S | 2025-12-03 | 1 | 0 | 0 | 0.00 | 0.00 | 0.00 |
| 2026Q3 | S | 2025-11-11 | 1 | 0 | 0 | 0.00 | 0.00 | 0.00 |
| 2026Q3 | S | 2025-11-10 | 1 | 0 | 0 | 0.00 | 0.00 | 0.00 |
| 2026Q3 | S | 2025-11-09 | 1 | 0 | 0 | 0.00 | 0.00 | 0.00 |
| 2026Q3 | S | 2025-11-08 | 1 | 0 | 0 | 0.00 | 0.00 | 0.00 |
| 2026Q3 | S | 2025-11-07 | 1 | 0 | 0 | 0.00 | 0.00 | 0.00 |
| 2026Q3 | S | 2025-11-06 | 1 | 0 | 0 | 0.00 | 0.00 | 0.00 |
| 2026Q3 | S | 2025-11-05 | 1 | 0 | 0 | 0.00 | 0.00 | 0.00 |
| 2026Q3 | S | 2025-11-04 | 1 | 0 | 0 | 0.00 | 0.00 | 0.00 |
| 2026Q3 | S | 2025-11-03 | 1 | 0 | 0 | 0.00 | 0.00 | 0.00 |
| 2026Q3 | S | 2025-11-02 | 1 | 0 | 0 | 0.00 | 0.00 | 0.00 |
Estimate history
| EPS, annual | -0.573 | -1.169 | -0.572 | -0.987 | -1.326 | -2.069 | -1.9479 | ||
|---|---|---|---|---|---|---|---|---|---|
| Period | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
| EPS, quarterly | -0.138 | -0.571 | -0.499 | -0.556 | -0.578 | -0.484 | -0.459 | -0.551 | -0.454 |
| Period | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
| Sales, annual | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Period | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
| Sales, quarterly | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Period | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
| Shares, annual | 1.835 | 1.835 | 1.835 | 1.835 | 1.962 | 2.974 | 3.06 | ||
| Period | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | MRQ | ||
| Shares, quarterly | 1.835 | 1.835 | 1.962 | 2.261 | 2.535 | 2.974 | 2.974 | 3.059 | 3.06 |
| Period | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
Income statement, annual
| Metric | TTM | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY | 2020FY |
|---|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Goods Sold Incl. D&A | 0.14 | 0.16 | 0.16 | 0.16 | 0.16 | 0.10 | 0.00 |
| Gross Profit | -0.14 | -0.16 | -0.16 | -0.16 | -0.16 | -0.10 | 0.00 |
| Selling, General and Administrative Excl. Other | 5.53 | 5.21 | 2.18 | 1.55 | 0.41 | 1.84 | 1.05 |
| Research and Development | 2.45 | 2.13 | 0.41 | 0.08 | 0.09 | 0.18 | 0.02 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -5.67 | -5.37 | -2.34 | -1.71 | -0.57 | -1.94 | -1.05 |
| Interest Expense | 0.00 | 0.00 | 0.86 | 0.10 | 0.48 | 0.20 | 0.01 |
| Unusual Expense | 0.29 | 0.20 | -0.60 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Before Taxes | -5.80 | -5.45 | -2.60 | -1.81 | -1.05 | -2.15 | -1.05 |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | -5.80 | -5.45 | -2.60 | -1.81 | -1.05 | -2.15 | -1.05 |
| Net Income From Continuing Operations | -5.80 | -5.45 | -2.60 | -1.81 | -1.05 | -2.15 | -1.05 |
| Net Income | -5.80 | -5.45 | -2.60 | -1.81 | -1.05 | -2.15 | -1.05 |
| EPS (Recurring) | -1.83 | -2.02 | -1.54 | -0.99 | -0.57 | -1.17 | -0.57 |
| EPS (Basic, Before Extraordinaries) | -1.95 | -2.07 | -1.33 | -0.99 | -0.57 | -1.17 | -0.57 |
| EPS (Diluted) | -1.95 | -2.07 | -1.33 | -0.99 | -0.57 | -1.17 | -0.57 |
| EBITDA | -5.53 | -5.21 | -2.18 | -1.55 | -0.41 | -1.84 | -1.05 |
| Non-Operating Income (Expense) | 0.15 | 0.12 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 0.45 | 0.27 | 0.22 | - | - | 0.30 | 0.80 |
| Shares Outstanding | 3.06 | 2.97 | 1.96 | 1.84 | 1.84 | 1.84 | 1.84 |
| Market Capitalization | 1.73 | 1.73 | 20.88 | 20.04 | - | - | - |
Income statement, quarterly
| Metric | 2026Q2 | 2026Q1 | 2025Q4 | 2025Q3 | 2025Q2 | 2025Q1 | 2024Q4 | 2024Q3 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Goods Sold Incl. D&A | 0.02 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 |
| Gross Profit | -0.02 | -0.04 | -0.04 | -0.04 | -0.04 | -0.04 | -0.04 | -0.04 |
| Selling, General and Administrative Excl. Other | 1.31 | 1.58 | 1.32 | 1.32 | 1.34 | 1.23 | 1.41 | 0.34 |
| Research and Development | 0.62 | 0.68 | 0.54 | 0.61 | 0.50 | 0.49 | 0.17 | 0.01 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -1.33 | -1.62 | -1.36 | -1.36 | -1.38 | -1.27 | -1.45 | -0.38 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.13 | 0.66 |
| Unusual Expense | 0.09 | 0.07 | 0.05 | 0.07 | 0.08 | 0.00 | -0.60 | 0.00 |
| Net Income Before Taxes | -1.39 | -1.65 | -1.36 | -1.40 | -1.42 | -1.26 | -0.98 | -1.05 |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | -1.39 | -1.65 | -1.36 | -1.40 | -1.42 | -1.26 | -0.98 | -1.05 |
| Net Income From Continuing Operations | -1.39 | -1.65 | -1.36 | -1.40 | -1.42 | -1.26 | -0.98 | -1.05 |
| Net Income | -1.39 | -1.65 | -1.36 | -1.40 | -1.42 | -1.26 | -0.98 | -1.05 |
| EPS (Recurring) | -0.43 | -0.53 | -0.45 | -0.47 | -0.56 | -0.56 | -0.71 | -0.57 |
| EPS (Basic, Before Extraordinaries) | -0.45 | -0.55 | -0.46 | -0.48 | -0.58 | -0.56 | -0.50 | -0.57 |
| EPS (Diluted) | -0.45 | -0.55 | -0.46 | -0.48 | -0.58 | -0.56 | -0.50 | -0.57 |
| EBITDA | -1.31 | -1.58 | -1.32 | -1.32 | -1.34 | -1.23 | -1.41 | -0.34 |
| Non-Operating Income (Expense) | 0.03 | 0.04 | 0.05 | 0.04 | 0.03 | 0.00 | 0.00 | 0.00 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 0.14 | 0.14 | 0.11 | 0.05 | 0.06 | 0.08 | 0.18 | - |
| Shares Outstanding | 3.06 | 3.06 | 2.97 | 2.97 | 2.53 | 2.26 | 1.96 | 1.84 |
| Market Capitalization | 1.73 | 11.97 | 14.78 | 24.36 | 12.58 | 14.82 | 20.88 | 20.17 |
Balance sheet, annual
| Metric | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY | 2020FY |
|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 4.49 | 1.27 | 0.09 | 0.44 | 0.07 | 0.01 |
| Short Term Receivables | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.90 | 2.90 | 0.01 | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 5.39 | 4.17 | 0.10 | 0.44 | 0.07 | 0.01 |
| Net Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Investments and Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Intangible Assets | 0.06 | 0.22 | 0.38 | 0.54 | 0.70 | 0.00 |
| Deferred Tax Assets | 0.24 | 0.45 | - | - | - | - |
| Other Assets | 1.09 | 1.38 | 0.48 | 0.06 | 0.00 | 0.00 |
| Total Assets | 6.78 | 6.22 | 0.96 | 1.04 | 0.78 | 0.01 |
| Short Term Debt Incl. Current Port. of LT Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.38 | 0.05 |
| Accounts Payable | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Liabilities | 0.20 | 0.99 | 2.40 | 1.63 | 1.56 | 0.31 |
| Total Current Liabilities | 0.20 | 0.99 | 2.40 | 1.63 | 1.94 | 0.36 |
| Long Term Debt | 0.00 | 0.00 | 0.64 | 0.58 | 0.00 | 0.00 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Tax Liabilities | 0.24 | 0.45 | - | - | - | - |
| Other Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 0.44 | 1.44 | 3.04 | 2.21 | 1.94 | 0.36 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 6.34 | 4.78 | -2.08 | -1.18 | -1.17 | -0.34 |
| Total Shareholders Equity | 6.34 | 4.78 | -2.08 | -1.18 | -1.17 | -0.34 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 6.34 | 4.78 | -2.08 | -1.18 | -1.17 | -0.34 |
| Total Liabilities & Stockholders Equity | 6.78 | 6.22 | 0.96 | 1.04 | 0.78 | 0.01 |
| Book Value Per Share | 2.13 | 2.43 | -1.13 | -0.64 | -0.64 | -0.19 |
| Tangible Book Value Per Share | 2.11 | 2.32 | -1.34 | -0.94 | -1.02 | -0.19 |
| Full-Time Employees | 4 | 4 | 3 | - | 3 | - |
| Price to Book Ratio | 0.37 | 4.37 | 6.01 | - | - | - |
| Return on Assets | -83.83 | -72.50 | -181.11 | -115.96 | -543.51 | - |
| Return on Equity | -97.99 | -192.96 | - | - | - | - |
| Return on Invested Capital | -85.90 | -54.50 | - | - | - | - |
| Quick Ratio | 27.07 | 4.20 | 0.04 | 0.27 | 0.04 | 0.04 |
| Current Ratio | 27.07 | 4.20 | 0.04 | 0.27 | 0.04 | 0.04 |
Cash flow, annual
| Metric | TTM | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY | 2020FY |
|---|---|---|---|---|---|---|---|
| Net Income | -5.80 | -5.45 | -2.60 | -1.81 | -1.05 | -2.15 | -1.05 |
| Depreciation | 0.14 | 0.16 | 0.16 | 0.16 | 0.16 | 0.10 | 0.00 |
| Other Funds (Non Cash) | 2.15 | 2.65 | 0.47 | 0.97 | 0.41 | 0.44 | 0.80 |
| Funds from Operations | -3.51 | -2.63 | -1.97 | -0.68 | -0.48 | -1.60 | -0.25 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | -0.46 | -0.81 | -1.98 | 0.76 | 0.13 | 1.19 | 0.21 |
| Cash from Operating Activities | -3.97 | -3.44 | -3.96 | 0.08 | -0.35 | -0.41 | -0.04 |
| Capital Expenditures | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
| Purchase or Sale of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale Or Maturity of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.12 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.11 | 0.00 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 3.56 | 6.66 | 5.13 | -0.42 | -0.06 | 0.25 | 0.00 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 3.56 | 6.66 | 5.13 | -0.42 | -0.06 | 0.25 | 0.00 |
| Proceedsfrom Stock Options | 3.56 | 3.60 | 5.13 | -0.42 | -0.06 | 0.25 | 0.00 |
| Issuance or Reduction of Debt, Net | 0.00 | 0.00 | 0.00 | 0.00 | 0.78 | 0.33 | 0.05 |
| Change in Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.78 | 0.33 | 0.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.14 | 0.00 | 0.81 | 0.35 | 0.00 |
| Reduction of Long Term Debt | 0.00 | 0.00 | -0.14 | 0.00 | -0.03 | -0.02 | 0.00 |
| Net Financing Active Other Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | -0.01 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | -0.01 |
| Cash from Financing Activities | 3.56 | 6.66 | 5.13 | -0.42 | 0.72 | 0.58 | 0.04 |
| Net Change in Cash | -0.41 | 3.22 | 1.18 | -0.34 | 0.36 | 0.06 | -0.00 |
| Free Cash Flow | - | -3.44 | -3.96 | 0.08 | -0.35 | -0.41 | -0.04 |
| Preferred Dividends (Cash Flow) | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Taxes & Investment Tax Credit | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Balance sheet, quarterly
| Metric | 2026Q2 | 2026Q1 | 2025Q4 | 2025Q3 | 2025Q2 | 2025Q1 |
|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 2.63 | 3.67 | 4.49 | 5.58 | 3.03 | 3.62 |
| Short Term Receivables | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.55 | 0.77 | 0.90 | 1.08 | 1.80 | 2.43 |
| Total Current Assets | 3.17 | 4.44 | 5.39 | 6.66 | 4.84 | 6.05 |
| Net Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Investments and Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Intangible Assets | 0.00 | 0.02 | 0.06 | 0.10 | 0.14 | 0.18 |
| Deferred Tax Assets | - | - | 0.24 | - | - | - |
| Other Assets | 1.28 | 1.28 | 1.09 | 1.31 | 1.69 | 1.71 |
| Total Assets | 4.46 | 5.74 | 6.78 | 8.07 | 6.67 | 7.94 |
| Short Term Debt Incl. Current Port. of LT Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Accounts Payable | 0.27 | 0.43 | 0.00 | 0.40 | 0.68 | 0.81 |
| Other Current Liabilities | 0.00 | 0.00 | 0.20 | 0.00 | 0.00 | 0.00 |
| Total Current Liabilities | 0.27 | 0.43 | 0.20 | 0.40 | 0.68 | 0.81 |
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Tax Liabilities | - | - | 0.24 | - | - | - |
| Other Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 0.27 | 0.43 | 0.44 | 0.40 | 0.68 | 0.81 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 4.19 | 5.31 | 6.34 | 7.66 | 6.00 | 7.13 |
| Total Shareholders Equity | 4.19 | 5.31 | 6.34 | 7.66 | 6.00 | 7.13 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 4.19 | 5.31 | 6.34 | 7.66 | 6.00 | 7.13 |
| Total Liabilities & Stockholders Equity | 4.46 | 5.74 | 6.78 | 8.07 | 6.67 | 7.94 |
| Book Value Per Share | 1.37 | 1.74 | 2.13 | 2.58 | 2.37 | 3.15 |
| Tangible Book Value Per Share | 1.37 | 1.73 | 2.11 | 2.54 | 2.31 | 3.07 |
| Full-Time Employees | - | - | 4 | - | - | - |
| Price to Book Ratio | 0.37 | 2.25 | 2.33 | 3.18 | 2.10 | 2.08 |
| Return on Assets | -104.32 | -85.36 | -83.83 | -77.46 | -122.32 | -79.52 |
| Return on Equity | -113.96 | -93.84 | -97.99 | -92.07 | -281.84 | -149.74 |
| Return on Invested Capital | -33.12 | -31.13 | -21.53 | -18.24 | -23.71 | -17.69 |
| Quick Ratio | 11.98 | 10.31 | 27.07 | 16.56 | 7.16 | 7.52 |
| Current Ratio | 11.98 | 10.31 | 27.07 | 16.56 | 7.16 | 7.52 |
Cash flow, quarterly
| Metric | 2026Q2 | 2026Q1 | 2025Q4 | 2025Q3 | 2025Q2 | 2025Q1 |
|---|---|---|---|---|---|---|
| Net Income | -1.39 | -1.65 | -1.36 | -1.40 | -1.42 | -1.26 |
| Depreciation | 0.02 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 |
| Other Funds (Non Cash) | 0.47 | 0.48 | 0.47 | 0.73 | 1.38 | 0.08 |
| Funds from Operations | -0.89 | -1.14 | -0.85 | -0.63 | -0.01 | -1.15 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | -0.12 | 0.10 | -0.23 | -0.21 | -0.80 | 0.43 |
| Cash from Operating Activities | -1.01 | -1.04 | -1.08 | -0.84 | -0.81 | -0.71 |
| Capital Expenditures | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale Or Maturity of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Dividends (Cash Flow) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | -0.04 | 0.22 | 0.00 | 3.38 | 0.22 | 3.06 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | -0.04 | 0.22 | 0.00 | 3.38 | 0.22 | 3.06 |
| Proceedsfrom Stock Options | -0.04 | 0.22 | 0.00 | 3.38 | -2.83 | 3.06 |
| Issuance or Reduction of Debt, Net | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | -0.04 | 0.22 | 0.00 | 3.38 | 0.22 | 3.06 |
| Net Change in Cash | -1.05 | -0.82 | -1.08 | 2.54 | -0.58 | 2.34 |
| Free Cash Flow | -1.01 | -1.04 | -1.08 | - | - | -0.71 |
Revenue breakdown
| Revenue split | - |
|---|
Short interest
shares short against float, oldest to newest| Settlement | Of float | Shares short | Float | Avg volume |
|---|---|---|---|---|
| 2026-10-30 | 3.74% | 0.1M | 2.3M | 369.25K |
| 2026-10-15 | 5.98% | 0.1M | 2.3M | 541.02K |
| 2026-09-30 | 5.03% | 0.1M | 2.3M | 339.45K |
| 2026-09-15 | 5.08% | 0.1M | 2.3M | 329.05K |
| 2026-08-31 | 2.70% | 0.1M | 2.1M | 311.96K |
| 2026-08-14 | 2.45% | 0.1M | 2.1M | 308.86K |
| 2026-07-31 | 3.85% | 0.1M | 1.9M | 298.12K |
| 2026-07-15 | 1.43% | 0.0M | 1.9M | 100.65K |
| 2026-06-30 | 1.16% | 0.0M | 1.9M | 19.16K |
| 2026-06-15 | 1.22% | 0.0M | 1.8M | 18.46K |
| 2026-05-29 | 1.24% | 0.0M | 1.8M | 21.08K |
| 2026-05-15 | 0.96% | 0.0M | 1.8M | 71.95K |
| 2026-04-30 | 1.01% | 0.0M | 1.8M | 70.71K |
| 2026-04-15 | 1.18% | 0.0M | 1.8M | 73.02K |
| 2026-03-31 | 1.91% | 0.0M | 1.8M | 75.99K |
| 2026-03-13 | 1.65% | 0.0M | 1.7M | 77.63K |
| 2026-02-27 | 10.57% | 0.2M | 1.7M | 74.45K |
| 2026-02-13 | 1.51% | 0.0M | 1.7M | 22.31K |
| 2026-01-30 | 1.20% | 0.0M | 1.7M | 26.02K |
| 2026-01-15 | 1.59% | 0.0M | 1.7M | 28.39K |
Option chain
expiry 2026-11-11| Type | Strike | Bid | Ask | Last | IV | Open int | Volume | Delta | Theta | Vega |
|---|---|---|---|---|---|---|---|---|---|---|
| No option chain for this symbol. | ||||||||||
Latest SEC filings
30| Filed | Form | Description | Period | Link |
|---|---|---|---|---|
| 2026-11-05 | 8-K | Current report | 2026-11-05 | SEC |
| 2026-11-03 | 8-K | Current report | 2026-10-29 | SEC |
| 2026-10-06 | 8-K | Current report | 2026-10-06 | SEC |
| 2026-09-14 | 8-K | Current report | 2026-09-14 | SEC |
| 2026-08-21 | 8-K | Current report | 2026-08-21 | SEC |
| 2026-08-12 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-06-30 | SEC |
| 2026-07-22 | 8-K | Current report | 2026-07-16 | SEC |
| 2026-07-15 | 8-K | Current report | 2026-07-15 | SEC |
| 2026-06-30 | 8-K | Current report | 2026-06-29 | SEC |
| 2026-06-04 | 8-K | Current report | 2026-06-04 | SEC |
| 2026-05-26 | DEFA14A | Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 | SEC | |
| 2026-05-22 | ARS | Annual report to security holders. | 2025-12-31 | SEC |
| 2026-05-22 | DEF 14A | Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 | 2026-05-22 | SEC |
| 2026-05-18 | 8-K | Current report | 2026-05-18 | SEC |
| 2026-05-13 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-03-31 | SEC |
| 2026-05-11 | PRE 14A | Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 | 2026-05-11 | SEC |
| 2026-04-01 | 424B3 | SEC | ||
| 2026-04-01 | 424B3 | SEC | ||
| 2026-03-31 | 10-K | Annual report pursuant to Section 13 or 15(d) | 2025-12-31 | SEC |
| 2026-03-02 | 8-K | Current report | 2026-03-02 | SEC |
| 2026-02-26 | 8-K | Current report | 2026-02-26 | SEC |
| 2026-01-23 | EFFECT | Effectiveness filing by commission order | SEC | |
| 2026-01-21 | CORRESP | SEC | ||
| 2026-01-15 | UPLOAD | Upload Submission | SEC | |
| 2026-01-13 | S-3 | Registration statement for specified transactions by certain issuers including face-amount certificate companies | SEC | |
| 2025-12-30 | 4 | Statement of changes in beneficial ownership of securities | 2025-10-08 | SEC |
| 2025-12-23 | 4 | Statement of changes in beneficial ownership of securities | 2025-09-16 | SEC |
| 2025-11-26 | 4 | Statement of changes in beneficial ownership of securities | 2025-10-08 | SEC |
| 2025-11-26 | 4 | Statement of changes in beneficial ownership of securities | 2025-09-16 | SEC |
| 2025-11-26 | 4 | Statement of changes in beneficial ownership of securities | 2025-10-08 | SEC |
Insider activity by month
| Month | Bought | Buys | Sold | Sells |
|---|---|---|---|---|
| 2026-11 | 0 | 0 | 0 | 0 |
| 2026-10 | 0 | 0 | 0 | 0 |
| 2026-09 | 0 | 0 | 0 | 0 |
| 2026-08 | 0 | 0 | 0 | 0 |
| 2026-07 | 0 | 0 | 0 | 0 |
| 2026-06 | 0 | 0 | 0 | 0 |
| 2026-05 | 0 | 0 | 0 | 0 |
| 2026-04 | 0 | 0 | 0 | 0 |
| 2026-03 | 0 | 0 | 0 | 0 |
| 2026-02 | 0 | 0 | 0 | 0 |
| 2026-01 | 0 | 0 | 0 | 0 |
| 2025-12 | 0 | 0 | 0 | 0 |
| 2025-11 | 0 | 0 | 0 | 0 |
Institutional holders
| Manager | % owned |
|---|---|
| CITADEL ADVISORS LLC | 1.45% |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.08% |
| Virtu Financial LLC | 0.38% |
| GEODE CAPITAL MANAGEMENT, LLC | 0.37% |
| VANGUARD FIDUCIARY TRUST CO | 0.30% |
| Aptus Capital Advisors, LLC | 0.21% |
| SevenBridge Financial Group, LLC | 0.21% |
| JANE STREET GROUP, LLC | 0.16% |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.14% |
| STATE STREET CORP | 0.11% |
Funds
| Fund | % owned |
|---|---|
| VANGUARD INSTITUTIONAL TOTAL STOCK MARKET INDEX FUND | 0.77% |
| VANGUARD EXTENDED MARKET INDEX FUND | 0.32% |
| Fidelity Extended Market Index Fund | 0.20% |
| Fidelity Series Total Market Index Fund | 0.03% |
| Blackstone Alternative Multi-Strategy Fund | 0.00% |
OakChart. KAPA. Cached 15 minutes.
Some panels did not load: ratings, insider.